Using a biosimilar can produce substantial cost savings in patients who are receiving infliximab therapy for inflammatory diseases like rheumatoid arthritis (RA), but dose escalations, which are frequent for those who use infliximab, can increase the cost of therapy, even with a biosimilar.
Using a biosimilar can produce substantial cost savings in patients who are receiving infliximab therapy for inflammatory diseases like rheumatoid arthritis (RA), but dose escalations, which are frequent for those who use infliximab, can increase the cost of therapy, even with a biosimilar.
Recently, in a paper appearing this month in Arthritis Research and Therapy, investigators studied the frequency of dose escalation with biosimilar infliximab versus using an alternative agent—like golimumab—that is subject to fewer dose escalations.
In the study, the authors assembled 2 cohorts of Medicare beneficiaries with RA who were starting treatment with either infliximab (n = 5147) or intravenous golimumab (n = 2843). They used CMS fee-for-service Medicare data from 2012 to 2016 to compare dose escalation (defined as a dose increase of 100 mg or more for infliximab or 50 mg or more for golimumab, or increased frequency of dosing), persistence, and the cost to Medicare.
A hypothetical modeling scenario was used to compare dose-escalated infliximab versus golimumab using Medicare-approved amounts in the first quarter of 2016 to evaluate the extent to which dose escalation would be needed before it offset higher Medicare-approved payment a mounts for golimumab, and the model took into account potential discounts for biosimilar infliximab.
They found that dose escalation occurred in 49% of patients receiving infliximab, versus just 5% of those receiving golimumab. Physician ownership of infusion centers was associated with an increased likelihood that infliximab doses would be increased (odds ratio, 1.25; 95% CI, 1.09-1.44).
The mean costs paid by Medicare over the initial 18 months of treatment were higher for golimumab ($28,146, standard deviation [SD]; $16,030) than for infliximab ($21,216; SD, $15,819). Among patients who persisted with treatment through 18 months, least square mean costs were $43,940 for golimumab and $34,671 for infliximab.
In the modeling scenario used to evaluate the level of dosing that would be required to offset higher costs of golimumab use, all dosing frequencies of infliximab at doses of either 3 mg/kg or 5 mg/kg yielded lower annual costs than golimumab. At 10 mg/kg every 6 weeks, infliximab became more costly than golimumab unless discounts of 30% of higher were applied. At 10 mg/kg every 4 weeks, discounts of 50% of greater would be necessary. Given the 21% average sales price discount of the biosimilar Inflectra in 2019, even a dose of infliximab at 8 mg/kg every 6 weeks would be cost-neutral or cost-saving versus golimumab.
The authors conclude that, “costs associated with dose escalating infliximab to 10 mg/kg every 4 or 6 weeks are substantial and likely offset even appreciable dose savings associated with biosimilars,” and, in patients who require such escalations, using an alternative therapy is likely to be less expensive while achieving similar outcomes. For all other lower doses, costs associated with dose escalation are likely to be offset by biosimilar savings.
Reference
Curtis JR, Xie F, Kay J, Kallich JD. Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis [published online December 12, 2019]. Arthritis Res Ther. doi: 10.1186/s13075-019-2022-8.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.